ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO660

Healthcare Resource Utilization (HCRU) in Prevalent Dialysis Patients Undergoing Peritoneal Dialysis in the United States

Session Information

  • Home Dialysis - II
    November 04, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Dialysis

  • 802 Dialysis: Home Dialysis and Peritoneal Dialysis

Authors

  • Rouette, Julie, GSK, Montreal, Quebec, Canada
  • Wetmore, James B., Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, Minnesota, United States
  • Wetten, Sally, GSK, Brentford, Middlesex, United Kingdom
  • Guo, Haifeng, Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, Minnesota, United States
  • Requena, Gema, GSK, Brentford, Middlesex, United Kingdom
  • Li, Suying, Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, Minnesota, United States
  • Mu, George, GSK, Collegeville, Pennsylvania, United States
  • Ma, Liyuan, GSK, Collegeville, Pennsylvania, United States
  • Fairburn-Beech, Jolyon, GSK, Brentford, Middlesex, United Kingdom
  • Gilbertson, David T., Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, Minnesota, United States
  • Richards, Anna, GSK, Brentford, Middlesex, United Kingdom
  • Liu, Jiannong, Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, Minnesota, United States
Background

CKD is associated with increased HCRU. The US prevalence of patients (pts) undergoing peritoneal dialysis (PD) has more than doubled since 2000. We characterized the HCRU rate in prevalent PD pts in the US.

Methods

This observational cohort study used 2017–2019 United States Renal Data System data. Adults (≥18 years [yrs]) undergoing PD on Jan, 1 2018 (index) and with 6 months of Medicare fee-for-service coverage prior to index (incl.) were included. Follow-up was from index until death, loss of Medicare coverage, kidney transplantation, or Dec 31, 2019. All-cause HCRU was measured as the total number of services provided/total follow-up time (rate per patient-year [PY]).

Results

20,647 PD pts were included (median age, 62.2 yrs; median dialysis duration, 2.7 yrs; Table 1). Diabetes was the most prevalent comorbidity (55.4%) and cause of ESKD (39.9%). Median follow-up was 2 yrs. During follow-up, rate of hospitalization was 1.52 per PY; of intensive care unit use 0.37; of skilled nursing facility (SNF) use 0.29; and of emergency department (ED) encounters 1.09 (Table 2). Consultation rates were highest for nephrologists (15.72). Pts treated in units with the largest numbers of pts (>100) had generally lower HCRU; pts outside of large metro areas had a lower hospitalization, but higher outpatient and ED encounters rates.

Conclusion

In the US, PD pts had 1.52 hospitalizations and 1.09 ED encounters per PY. Pts treated in units with >100 pts had generally lower HCRU rates.

Funding

  • Commercial Support – Funded by GSK (Study 213716)